8-KAcquisitions & DispositionsRegulation FDExhibits & Filings

PFIZER INC 8-K Report, Acquisition Completed (Sep 3, 2015)

Filed September 3, 2015For Securities:PFE

Summary

Pfizer Inc. (PFE) has officially completed its acquisition of Hospira, Inc., a leader in injectable drugs and infusion technologies, through a merger that became effective on September 3, 2015. This strategic move sees Hospira become a wholly-owned subsidiary of Pfizer. Under the terms of the merger, Hospira shareholders will receive $90.00 in cash for each share of Hospira common stock they hold, excluding certain treasury, PFE-owned, or dissenting shares. This acquisition significantly enhances Pfizer's business, particularly in the area of biosimilars and sterile injectable products, aligning with the company's strategy to expand its portfolio and market presence in key therapeutic areas. Investors should note that this is a cash-and-carry transaction, meaning no stock is being issued by Pfizer, and the financial impact will be primarily through the integration of Hospira's operations and its contribution to Pfizer's revenue and earnings.

Key Highlights

  • 1Pfizer Inc. completed the acquisition of Hospira, Inc. on September 3, 2015.
  • 2Hospira is now a wholly-owned subsidiary of Pfizer.
  • 3Hospira shareholders will receive $90.00 in cash per share.
  • 4The merger was executed via an Agreement and Plan of Merger dated February 5, 2015.
  • 5This acquisition strengthens Pfizer's position in biosimilars and sterile injectables.
  • 6The filing includes an exhibit of the press release announcing the merger completion.

Frequently Asked Questions

The primary financial impact is through the integration of Hospira's operations into Pfizer's business, aiming to enhance revenue and earnings. Since this is a cash acquisition, there is no dilution from stock issuance for existing Pfizer shareholders. The cash outlay of $90.00 per Hospira share represents a significant investment in expanding Pfizer's product portfolio.

Hospira is a leading provider of injectable drugs and infusion technologies. Its acquisition by Pfizer is expected to significantly bolster Pfizer's presence in biosimilars and sterile injectable products, areas that are strategically important for the company's growth.

The merger between Pfizer and Hospira officially became effective on September 3, 2015.

While the 8-K filing states the per-share cash consideration is $90.00, it does not explicitly state the total transaction value. However, based on the merger agreement and prior announcements (February 2015), the total deal was valued at approximately $17 billion.